$MAJI News

Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition

Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization

Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement

Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms

Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value

Exousia Pro Announces Breakthrough In Exosome-Based Delivery

Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA

Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes

Exousia Pro Reports Positive Outcome in Legal Proceeding

Exousia Pro Files Provisional Patent for Novel Extracellular Vesicle Loading Method, Tapping into Multi-Billion Dollar Markets

Exousia Pro Announces Strategic Acquisition to Launch a New Telehealth Division

Exousia Pro Creates New Subdivisions

Exousia Pro Files Reg A.

Exousia Pro Expands its Scientific Advisory Board

Exousia Pro Will Launch a Web Series with Our New Consultant

Exousia Pro Finishes Preclinical Trial for Glioblastoma Ahead of Schedule - Bolstering Orphan Drug Application

Exousia Pro CSO Revealed Significant Findings About the Glioblastoma Study in a Spaces Interview

Exousia Pro Offers Guidance on New Subdivisions

Exousia Pro to Deliver 500 Billion Dried Exosomes for Trade Show

Exousia Pro Issues Update on Name Change